DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
NOVA-22007 is an investigational drug.
There have been 24 clinical trials for NOVA-22007. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2012.
The most common disease conditions in clinical trials are Diabetes Mellitus, Insulin Resistance, and Disease. The leading clinical trial sponsors are Canadian Institutes of Health Research (CIHR), Canadian Network for Observational Drug Effect Studies, CNODES, and Drug Safety and Effectiveness Network, Canada.
There are two US patents protecting this investigational drug and forty-five international patents.
Recent Clinical Trials for NOVA-22007
|Trial of Maintenance With Niraparib- Uterine Serous Carcinoma||Tesaro, Inc.||Phase 2|
|Trial of Maintenance With Niraparib- Uterine Serous Carcinoma||Northwell Health||Phase 2|
|Lisdexamfetamine for Adults With Bulimia Nervosa||Nova Scotia Health Authority||Phase 2|
Top disease conditions for NOVA-22007
Top clinical trial sponsors for NOVA-22007
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|NOVA-22007||Start Trial||Methods for determining risk of chronic lung allograft dysfunction (CLAD) and subtypes thereof||University Health Network (Toronto, CA)||Start Trial|
|NOVA-22007||Start Trial||Advanced analyte sensor calibration and error detection||DexCom, Inc. (San Diego, CA)||Start Trial|
|NOVA-22007||Start Trial||Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same||SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)||Start Trial|
|NOVA-22007||Start Trial||Substituted indole Mcl-1 inhibitors||Vanderbilt University (Nashville, TN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|NOVA-22007||European Patent Office||2959017||2033-02-20||Start Trial|
|NOVA-22007||World Intellectual Property Organization (WIPO)||2014127463||2033-02-20||Start Trial|
|NOVA-22007||European Patent Office||2697650||2031-04-15||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|